CASI Pharmaceuticals Stock Analysis


USD 1.95  0.02  1.02%   

The big decline in price over the last few months for CASI Pharmaceuticals could raise concerns from stockholders as the entity is trading at a share price of 1.95 on very low momentum in volume. The company directors and management failed to add value to investors and position the entity supply of money to exploit market volatility in November. However, diversifying your holdings with CASI Pharmaceuticals or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.5. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the CASI Pharmaceuticals partners.
Continue to Trending Equities.
The CASI Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about CASI Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. CASI Pharmaceuticals Stock analysis module also helps to analyze the CASI Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

CASI Pharmaceuticals Stock Analysis Notes

About 33.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. CASI Pharmaceuticals recorded a loss per share of 2.26. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 2nd of June 2022. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland. Casi Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 176 people. For more info on CASI Pharmaceuticals please contact Ken Ren at 240 864 2600 or go to

CASI Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. CASI Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding CASI Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
CASI Pharmaceuticals generated a negative expected return over the last 90 days
CASI Pharmaceuticals may become a speculative penny stock
CASI Pharmaceuticals has high historical volatility and very poor performance
The company reported the previous year's revenue of 30.17 M. Net Loss for the year was (36.65 M) with profit before overhead, payroll, taxes, and interest of 17.61 M.
CASI Pharmaceuticals currently holds about 24.57 M in cash with (26.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
CASI Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 33.0% of the company shares are held by company insiders

CASI Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by CASI Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CASI Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End29th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

CASI Pharmaceuticals Largest EPS Surprises

Earnings surprises can significantly impact CASI Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

CASI Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. CASI Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that CASI Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial CASI Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
12th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
21st of June 2022
Unclassified Corporate Event
26th of May 2022
Financial Statements and Exhibits. Other Events. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Material Modifications to Rights of Security Holders
25th of May 2022
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
24th of May 2022
Financial Statements and Exhibits. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
12th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of May 2022
Financial Statements and Exhibits. Other Events
28th of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition

CASI Pharmaceuticals Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as CASI Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CASI Pharmaceuticals backward and forwards among themselves. CASI Pharmaceuticals' institutional investor refers to the entity that pools money to purchase CASI Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zebra Capital Management LlcCommon Shares11.2 K33 K
Zebra Capital Management LlcCommon Shares11.2 K17 K
Zebra Capital Management LlcCommon Shares50.7 K127 K
Zebra Capital Management LlcCommon Shares52.5 K107 K
Zebra Capital Management LlcCommon Shares44.3 K137 K
Yintercept Hong Kong LtdCommon Shares16.2 K25 K
Xtx Topco LtdCommon Shares41.3 K49 K
Note, although CASI Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CASI Pharmaceuticals Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 26.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CASI Pharmaceuticals's market, we take the total number of its shares issued and multiply it by CASI Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

CASI Pharmaceuticals Profitablity

CASI Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase CASI Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, CASI Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, CASI Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of CASI Pharmaceuticals' profitability requires more research than a typical breakdown of CASI Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.73) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.89) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.01.
Last ReportedProjected for 2022
Return on Investment(50.14) (54.10) 
Return on Average Assets(27.56) (29.73) 
Return on Average Equity(44.15) (47.64) 
Return on Invested Capital(0.57) (0.58) 
Return on Sales(1.22) (1.31) 

Management Efficiency

The entity has return on total asset (ROA) of (0.155) % which means that it has lost $0.155 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.273) %, meaning that it created substantial loss on money invested by shareholders. CASI Pharmaceuticals management efficiency ratios could be used to measure how well casi pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -54.1. The current Return on Average Assets is estimated to decrease to -29.73. CASI Pharmaceuticals Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 76.33 Million. The current Goodwill and Intangible Assets is estimated to increase to about 12.5 M, while Asset Turnover is projected to decrease to 0.21.
Last ReportedProjected for 2022
Book Value per Share 6.21  6.12 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(1.78) (1.92) 
Price to Book Value 1.32  1.43 
Tangible Assets Book Value per Share 9.27  8.64 
Enterprise Value59.8 M61.4 M
Tangible Asset Value126.1 M136 M

Technical Drivers

As of the 3rd of December, CASI Pharmaceuticals shows the Mean Deviation of 3.23, coefficient of variation of (514.54), and Market Risk Adjusted Performance of (0.60). CASI Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices. Put another way, you can use this information to find out if the entity will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for CASI Pharmaceuticals, which can be compared to its rivals. Please confirm CASI Pharmaceuticals variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and semi variance to decide if CASI Pharmaceuticals is priced adequately, providing market reflects its regular price of 1.95 per share. Please also double-check CASI Pharmaceuticals total risk alpha, which is currently at (1.18) to validate the company can sustain itself in the future.

CASI Pharmaceuticals Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. CASI Pharmaceuticals Triple Exponential Moving Average indicator shows smoothing effect of CASI Pharmaceuticals price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

CASI Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CASI Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on CASI Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CASI Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

CASI Pharmaceuticals Technical and Predictive Indicators

CASI Pharmaceuticals Forecast Models

CASI Pharmaceuticals time-series forecasting models is one of many CASI Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CASI Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About CASI Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how CASI Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CASI Pharmaceuticals shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as CASI Pharmaceuticals. By using and applying CASI Pharmaceuticals Stock analysis, traders can create a robust methodology for identifying CASI Pharmaceuticals entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 58.38  60.33 

Current CASI Pharmaceuticals Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CASI Pharmaceuticals analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CASI Pharmaceuticals analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.45Strong Buy4Odds
CASI Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most CASI Pharmaceuticals analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CASI Pharmaceuticals stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of CASI Pharmaceuticals, talking to its executives and customers, or listening to CASI Pharmaceuticals conference calls.
CASI Pharmaceuticals Analyst Advice Details

CASI Pharmaceuticals Stock Analysis Indicators

CASI Pharmaceuticals stock analysis indicators help investors evaluate how CASI Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading CASI Pharmaceuticals shares will generate the highest return on investment. By understating and applying CASI Pharmaceuticals stock analysis, traders can identify CASI Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow57064000.00
Common Stock Shares Outstanding110452000.00
Total Stockholder Equity84502000.00
DescriptionCASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a pallia
Total Cashflows From Investing Activities-20691000.00
Property Plant And Equipment Net21819000.00
Retained Earnings-605643000.00
Cash And Short Term Investments48572000.00
Retained Earnings Total Equity-605643000.00
Accounts Payable4789000.00
Net Debt-38704000.00
50 Day M A2.1946
Total Current Liabilities13186000.00
Currency CodeUSD
Other Operating Expenses72005000.00
Non Current Assets Total76328000.00
Common Stock Total Equity1399000.00
Non Currrent Assets Other2178000.00
Continue to Trending Equities. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running CASI Pharmaceuticals price analysis, check to measure CASI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CASI Pharmaceuticals is operating at the current time. Most of CASI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of CASI Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CASI Pharmaceuticals' price. Additionally, you may evaluate how the addition of CASI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is CASI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI Pharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
26.8 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine CASI Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.